An interventional study of HD-EEG recordings, combined with cognitive and motor assessment in Friedreich's Ataxia and Motor Disorders, sponsored by IRCCS Eugenio Medea. Recruiting at 1 site in Italy. Open to participants aged 8 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by IRCCS Eugenio Medea · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Friedreich Ataxia with a site in Italy — 5 open to participants now, 8 under way, 2 of them phase 3. Friedreich Ataxia · Italy.
Among the 22 studies in Friedreich Ataxia with a site in Italy, this one is the 10th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 with no phase, and was the 21st registered.
111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.
Browse Friedreich Ataxia studies →5 of the 22 studies in Friedreich Ataxia with a site in Italy are open now. Recruiting first, the newest first:
Lexeo Therapeutics · Sites in Italy, United States, Brazil and 6 more countries
Ages 6+
Lexeo Therapeutics · Sites in Italy, United States, Brazil and 5 more countries
Ages 6+
Biogen · Sites in Italy, United States, Austria and 4 more countries
Ages 16+
Friedreich's Ataxia Research Alliance · Sites in Italy, United States, Australia and 14 more countries
Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.
This study: 8 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 12 · Phase 3 4
First in 2008; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is close to the median of 30 across 76 interventional studies indexed under Friedreich Ataxia.
Median enrollment 36 across the 17 interventional studies, 300 across the 5 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
IRCCS Eugenio Medea is the lead sponsor of 109 studies on the registry; 52 are open to participants now.
IRCCS Eugenio Medea has 4 studies filed under Friedreich Ataxia — fewer than ten, so there is no comparison to draw.
3 of the studies in Friedreich Ataxia with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953583Phase 3BiogenA Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia | 2027-11-16 |
| NCT06692296IRCCS Eugenio MedeaEfficacy of Stabilometric Platform to Improve Standing Balance in Patients With Friedreich's Ataxia | 2026-12 |
| NCT06865482Lexeo TherapeuticsClinical Course Of Disease In Participants With FA-CM | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies in Friedreich Ataxia with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, exploratory, multicenter pilot study investigating the structural and functional connectome in patients with Friedreich's Ataxia (FRDA) using high-density electroencephalogram (HD-EEG). The aim is to identify neurophysiological biomarkers and analyze the relationship between cortical connectivity, cognitive functioning, and clinical severity, particularly in response to rehabilitation treatment.
Friedreich's Ataxia (FRDA) is a progressive neurodegenerative disease caused by mutations in the FXN gene, resulting in a reduction in the mitochondrial protein frataxin and a dysfunction in iron homeostasis. In addition to motor and sensory impairments, FRDA also results in cognitive and emotional deficits. Pathophysiologically, it is associated with cerebellar degeneration and alterations in cerebello-cortical networks.
The present study proposes a novel HD-EEG-based approach to analyze brain activity at resting-state and during the performance of a motor task (task-based) in subjects with FRDA. Thirty patients with confirmed genetic diagnosis, age between 8 and 60 years, and SARA score \<30 will be recruited. EEG recordings will be performed in resting condition and during an upper limb motor task.
In addition to neurophysiological measures, each participant will undergo a comprehensive neuropsychological evaluation, including memory, attention, language, visuospatial skills, praxis, executive functions, emotional and personality aspects. Connectivity data will be correlated with cognitive profiles and scores on the SARA and mFARS clinical scales.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
This arm includes patients with a confirmed genetic diagnosis of Friedreich's Ataxia (FRDA), aged between 8 and 60 years, with SARA scale scores below 30. Participants undergo high-density electroencephalogram (HD-EEG) recording under resting conditions and during a motor task, as well as a comprehensive neuropsychological and emotional assessment. All follow an intensive rehabilitation program lasting 3-4 weeks. HD-EEG recordings are repeated after treatment and one year later to assess longitudinal changes in functional connectivity and identify potential biomarkers associated with clinical progression.
Device: HD-EEG recordings, combined with cognitive and motor assessment
Participants will undergo high-density EEG (HD-EEG) recordings under two conditions: at rest and while performing an upper limb motor task. The data obtained will be used to reconstruct source cortical activity and derive patterns of functional connectivity, using advanced neurophysiological analysis techniques, including the Avalanche Transition Matrix (ATM). In addition, patients will complete a neuropsychological assessment and participate in an intensive multidisciplinary rehabilitation program lasting 3 to 4 weeks, depending on age. The intervention aims to assess changes in the functional organization of the brain before and after treatment, as well as one year later, in order to explore potential biomarkers of disease progression.
Connectivity profile derived from HD-EEG in subjects with FRDA.
Characterization of alterations in the connectome derived from the HD-EEG of subjects with FRDA compared with matched controls;
Time frame: From enrollment to the end of treatment at 3 to 4 weeks and after 1 year of follow-up
Functional activity derived from HD-EEG in subjects with FRDA.
Evaluation of functional connectivity as a biomarker in the evolution of FRDA
Time frame: From enrollment to the end of treatment at 3 to 4 weeks and after 1 year of follow-up
Correlation between functional connectivity/activity and quantitative parameters derived from neuropsychological scales. Correlation between functional connectivity/activity and quantitative parameters derived from motor scales (SARA and mFARS).
1. acquisition of new knowledge about the neuronal basis of impaired neurocognitive functioning in FRDA; 2. evaluation of possible correlations with disease severity scales pre- and post-rehabilitation treatment.
Time frame: From enrollment to the end of treatment at 3 to 4 weeks and after 1 year of follow-up
Plan to share: Yes — Anonymized individual participant data will be shared with other researchers upon reasonable request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Start date: January 2028 End date: January 2038
Access criteria: Any researchers accredited by non-profit clinical and research center
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.